but approvals of drugs with novel mechanisms of action for CNS disorders have been rare in recent years. Of course, drug discovery and development is inherently risky, with recent figures ...

Thousands of injured Victorian employees are receiving high-risk opioid prescriptions, Monash University-led research has found.Published in the ...

This not only makes eradication of the virus very difficult but also increases the risk of viral mutation, leading to drug resistance and treatment failure. One of these sites is the CNS.

The two companies will work together on the development of a “next-generation” of psychiatric medicines, although – for now – the drugs themselves and the target indications are being kept ...

CNS Pharmaceuticals expects to report primary ... Additionally, the Company has received Orphan Drug Designation from the FDA for using Berubicin to treat malignant glioma, which may provide ...

About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic ...

About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic ...

Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (“Tenacia”), a commercial-stage biopharmaceutical ...

Newleos Therapeutics Inc. was created by the Longwood Fund along with CNS drug developers Federico Bolognani and William Martin. The startup’s clinical-stage pipeline was licensed from Roche and ...

Buspirone can interact with other drugs, including antidepressants, monoamine oxidase inhibitors, opioids, and more.